How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Jul 3

PMID 31264691

Citations 13

Authors

David M Margolis

Steven G Deeks

Affiliations

Soon will be listed here.

Abstract

In this discussion, 2 established researchers and clinical trialists debate their opposing views on the utility, benefits, and risks of the use of analytical interruption of antiretroviral therapy as a clinical trial end point and outcome measure in human studies seeking to induce remission of or eradicate human immunodeficiency virus infection.

Citing Articles

A partner protection package for HIV cure-related trials involving analytical treatment interruptions.

Dube K, Morton T, Fox L, Dee L, Palm D, Villa T Lancet Infect Dis. 2023; 23(10):e418-e430.

PMID: 37295453 PMC: 10543569. DOI: 10.1016/S1473-3099(23)00267-0.

Prolonged viral suppression with anti-HIV-1 antibody therapy.

Gaebler C, Nogueira L, Stoffel E, Oliveira T, Breton G, Millard K Nature. 2022; 606(7913):368-374.

PMID: 35418681 PMC: 9177424. DOI: 10.1038/s41586-022-04597-1.

Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Dube K, Eskaf S, Barr L, Palm D, Hogg E, Simoni J AIDS Res Hum Retroviruses. 2022; 38(6):510-517.

PMID: 35323030 PMC: 9225827. DOI: 10.1089/AID.2021.0170.

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.

Lau J, Cromer D, Pinkevych M, Lewin S, Rasmussen T, McMahon J J Infect Dis. 2022; 226(2):236-245.

PMID: 35104873 PMC: 9400422. DOI: 10.1093/infdis/jiac032.

Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.

Gilbertson A, Tucker J, Dube K, Dijkstra M, Rennie S BMC Med Ethics. 2021; 22(1):169.

PMID: 34961509 PMC: 8714439. DOI: 10.1186/s12910-021-00716-1.

References

Murray J, Elashoff M, Cvetkovich T, Struble K . The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999; 13(7):797-804. DOI: 10.1097/00002030-199905070-00008. View

Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C . Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013; 9(3):e1003211. PMC: 3597518. DOI: 10.1371/journal.ppat.1003211. View

Persaud D, Gay H, Ziemniak C, Chen Y, Piatak Jr M, Chun T . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369(19):1828-35. PMC: 3954754. DOI: 10.1056/NEJMoa1302976. View

Henrich T, Hanhauser E, Marty F, Sirignano M, Keating S, Lee T . Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014; 161(5):319-27. PMC: 4236912. DOI: 10.7326/M14-1027. View

Hill A, Rosenbloom D, Fu F, Nowak M, Siliciano R . Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2014; 111(37):13475-80. PMC: 4169952. DOI: 10.1073/pnas.1406663111. View

Crowell T, Gebo K, Blankson J, Korthuis P, Yehia B, Rutstein R . Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. J Infect Dis. 2014; 211(11):1692-702. PMC: 4447832. DOI: 10.1093/infdis/jiu809. View

Crooks A, Bateson R, Cope A, Dahl N, Griggs M, Kuruc J . Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J Infect Dis. 2015; 212(9):1361-5. PMC: 4601910. DOI: 10.1093/infdis/jiv218. View

Laird G, Rosenbloom D, Lai J, Siliciano R, Siliciano J . Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay. Methods Mol Biol. 2015; 1354:239-53. DOI: 10.1007/978-1-4939-3046-3_16. View

10.

Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D . Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. PLoS One. 2017; 12(10):e0184441. PMC: 5624574. DOI: 10.1371/journal.pone.0184441. View

11.

Cromer D, Pinkevych M, Rasmussen T, Lewin S, Kent S, Davenport M . Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. J Virol. 2017; 91(24). PMC: 5709587. DOI: 10.1128/JVI.01395-17. View

12.

Henrich T, Hatano H, Bacon O, Hogan L, Rutishauser R, Hill A . HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017; 14(11):e1002417. PMC: 5675377. DOI: 10.1371/journal.pmed.1002417. View

13.

Wang X, Palmer S . Single-molecule techniques to quantify and genetically characterise persistent HIV. Retrovirology. 2018; 15(1):3. PMC: 5761141. DOI: 10.1186/s12977-017-0386-x. View